secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001193125-23-222977
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis announces 25% workforce reduction, expects up to $300M cost savings through 2024
--------------------------------------------------------------------------------

- Reduce workforce by ~225 employees (~25% of total); substantially complete in Q3 2023.
- Cost savings of up to $300M through 2024, including $70M+ from workforce reduction and up to $230M from external expenses.
- Focus on SYFOVRE U.S. launch and preparation for ex-U.S. launches; reduce EMPAVELI expenses.
- Prioritize retina and CNS research; deprioritize siRNA with systemic pegcetacoplan, APL-1030, APL-2006.
- Expect $9M-$11M cash costs for restructuring; update on cash runway in Q3 2023 earnings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523222977/0001193125-23-222977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523222977/d508238d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-222977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer